These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15306606)

  • 1. Is symptom control the correct end point for proton pump inhibitor treatment in Barrett's oesophagus?
    Sarela AI; Verbeke CS; Pring C; Guillou PJ
    Gut; 2004 Sep; 53(9):1387-8. PubMed ID: 15306606
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
    Cooper BT; Chapman W; Neumann CS; Gearty JC
    Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Porfimer sodium photodynamic therapy for management of Barrett's esophagus with high-grade dysplasia.
    Panjehpour M; Overholt BF
    Lasers Surg Med; 2006 Jun; 38(5):390-5. PubMed ID: 16788927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management strategies for Barrett's esophagus.
    Hillman L
    J Gastroenterol Hepatol; 2007 Jun; 22(6):771-2. PubMed ID: 17565627
    [No Abstract]   [Full Text] [Related]  

  • 6. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing dysplasia in Barrett's esophagus: are proton pump inhibitors the answer?
    Mardini HE
    Am J Gastroenterol; 2005 Apr; 100(4):978-9. PubMed ID: 15784046
    [No Abstract]   [Full Text] [Related]  

  • 8. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
    El-Serag HB; Aguirre T; Kuebeler M; Sampliner RE
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1255-60. PubMed ID: 15191506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
    Leedham S; Jankowski J
    Am J Gastroenterol; 2007 Jan; 102(1):21-3. PubMed ID: 17266685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
    Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
    Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention in Barrett's oesophagus.
    Gordon V; Jankowski J
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):569-79. PubMed ID: 22122772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid suppression and chemoprevention in Barrett's oesophagus.
    Raj A; Jankowski J
    Dig Dis; 2004; 22(2):171-80. PubMed ID: 15383758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.
    Overholt BF; Wang KK; Burdick JS; Lightdale CJ; Kimmey M; Nava HR; Sivak MV; Nishioka N; Barr H; Marcon N; Pedrosa M; Bronner MP; Grace M; Depot M;
    Gastrointest Endosc; 2007 Sep; 66(3):460-8. PubMed ID: 17643436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once or twice daily doses of proton pump inhibitor in treating Barrett's esophagus?
    Savarino V; Mela GS; Zentilin P; Celle G; Vigneri S
    Am J Gastroenterol; 1995 May; 90(5):845-6. PubMed ID: 7733108
    [No Abstract]   [Full Text] [Related]  

  • 15. Photofrin to treat precancerous lesions in Barrett's esophagus.
    FDA Consum; 2003; 37(6):4. PubMed ID: 14983805
    [No Abstract]   [Full Text] [Related]  

  • 16. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
    Sharma P; Sampliner RE; Camargo E
    Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results.
    Sharma P; Wani S; Weston AP; Bansal A; Hall M; Mathur S; Prasad A; Sampliner RE
    Gut; 2006 Sep; 55(9):1233-9. PubMed ID: 16905695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical treatment of gastroesophageal reflux with proton pump inhibitors].
    Vallot T; Carella G
    Gastroenterol Clin Biol; 1999 Jan; 23(1 Pt 2):S97-109. PubMed ID: 10078438
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
    Menges M; Müller M; Zeitz M
    Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barrett's oesophagus: the new endoscopic modalities have a future.
    Deviere J
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.